OncoMatch/Clinical Trials/NCT06356714
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
Is NCT06356714 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for colorectal cancer.
Treatment: Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens — Evaluate the efficacy and safety of Nocardia rubra cell wall skeleton in combination with prior second- or third-line regimens for the treatment of potentially hazardous colorectal cancer SD(Stable Disease) status in the real world.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: — second- or third-line therapy for advanced or metastatic colorectal cancer
Prior second- or third-line therapy for advanced or metastatic colorectal cancer
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 x 10^9/L; hemoglobin ≥ 9.0 g/dl; platelet count ≥ 100 x 10^9/L
Kidney function
serum creatinine ≤ 1.5 x ULN
Liver function
total bilirubin ≤ 1.5 x ULN; gammaglutaminase and alkaline phosphatase ≤ 3 x ULN (≤ 5 x ULN for patients with hepatic/liver metastases)
absolute neutrophil count ≥ 1.5 x 10^9 /L; hemoglobin ≥ 9.0 g/dl; platelet count ≥ 100 x 10^9 /L; total bilirubin ≤ 1.5 x ULN; gammaglutaminase and alkaline phosphatase ≤ 3 x ULN (≤ 5 x ULN for patients with hepatic/liver metastases); serum creatinine ≤ 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify